The activity of pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulphonamide derivatives in monolayer and spheroid breast cancer cell cultures. 2024

Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
Department of Biotechnology, Medical University of Bialystok, Bialystok, Poland.

In the last decade, an increasing interest in compounds containing pyrazolo[4,3-e][1,2,4]triazine moiety is observed. Therefore, the aim of the research was to synthesise a novel sulphonyl pyrazolo[4,3-e][1,2,4]triazines (2a, 2b) and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulphonamide derivatives (3a, 3b) to assess their anticancer activity. The MTT assay showed that 2a, 2b, 3a, 3b have stronger cytotoxic activity than cisplatin in both breast cancer cells (MCF-7 and MDA-MB-231) and exhibited weaker effect on normal breast cells (MCF-10A). The obtained results showed that the most active compound 3b increased apoptosis via caspase 9, caspase 8, and caspase 3/7. It is worth to note that compound 3b suppressed NF-κB expression and promoted p53, Bax, and ROS which play important role in activation of apoptosis. Moreover, our results confirmed that compound 3b triggers autophagy through increased formation of autophagosomes, expression of beclin-1 and mTOR inhibition. Thus, our study defines a possible mechanism underlying 3b-induced anti-cancer activity against breast cancer cell lines.

UI MeSH Term Description Entries
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines

Related Publications

Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
February 2023, International journal of molecular sciences,
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
May 2022, International journal of molecular sciences,
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
May 2023, International journal of molecular sciences,
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
June 2022, Molecules (Basel, Switzerland),
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
June 2023, International journal of molecular sciences,
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
January 2018, Medicinal chemistry (Shariqah (United Arab Emirates)),
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
August 2020, Molecules (Basel, Switzerland),
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
July 2010, Journal of hazardous materials,
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
May 2014, Bioorganic & medicinal chemistry,
Anna Szymanowska, and Dominika Radomska, and Robert Czarnomysy, and Mariusz Mojzych, and Katarzyna Kotwica-Mojzych, and Krzysztof Bielawski, and Anna Bielawska
January 2020, Molecules (Basel, Switzerland),
Copied contents to your clipboard!